Imaging With a New Agent That Finds a Cancer Protein Called HER2
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 4/21/2017 |
| Start Date: | March 31, 2017 |
| End Date: | March 2018 |
| Contact: | Gary Ulaner, MD, PhD |
| Email: | ulanerg@mskcc.org |
| Phone: | 212-639-3776 |
First-in-human Imaging With 89Zr-DFO-pertuzumab in Patients With HER2 Positive Malignancies
The purpose of this study is to test if an imaging agent called Zr-DFO-pertuzumab that finds
HER2 proteins can be used to take pictures of HER2-positive cancer.
HER2 proteins can be used to take pictures of HER2-positive cancer.
Inclusion Criteria:
- Age 21 years or greater
- Biopsy proven HER2-positive primary malignancy. ASCO guidelines will be used to
define HER2-positivity for breast cancer. Similar guidelines will be used for other
cancer types as appropriate.
- At least one malignant lesion on CT, MR, or FDG PET/CT within 60 days of protocol
enrollment
- ECOG performance of 0-2
Exclusion Criteria:
- Life expectancy < 3 months
- Pregnancy or lactation
- Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners
may not be able to function with patients over 450 pounds.
We found this trial at
1
site
205 East 64th Street
New York, New York 10065
New York, New York 10065
Principal Investigator: Gary Ulaner, MD, Ph.D.
Phone: 212-639-3776
Click here to add this to my saved trials
